• Print

Robin L. Teskin

2318 Mill Road
Suite 1100
Alexandria, Virginia 22314
Phone:  703.647.5911
Mobile Phone:  703.408.0043
Fax:  703.647.5958


Ms. Teskin focuses her practice on intellectual property law, with a particular emphasis on patent law in the biotechnology and pharmaceutical industries. Her experience involves all aspects of patent counseling and patent prosecution, including providing freedom-to-operate, due diligence, noninfringement and invalidity opinions. She advises a wide range of clients, including established and start-up biotechnology and pharmaceutical companies and prominent research universities.

Ms. Teskin has about 30 years of patent law experience which includes significant experience in complex patent office proceedings involving multiple parties such as reissue, reexamination, opposition and interference proceedings. Through her representation of a major pharmaceutical company at the forefront of drug formulation research, she also has an extensive background in Hatch-Waxman legal issues.

Prior to her admission to the bar, Ms. Teskin served as a patent examiner at the U.S. Patent and Trademark Office, where she was a member of the Biotechnology Group. She issued over four hundred-fifty patents dealing with complex biotechnology research and received a Bronze Medal for distinguished federal service.

Representative Experience

  • Managed patent prosecution worldwide on behalf of prominent biotech company involved in therapeutic antibody development including intellectual property relating to a chimeric antibody approved for the treatment of non-Hodgkin's lymphoma as well as a radiolabelled antibody approved for the treatment of cancer.
  • Represented prominent research university in an interference at the patent and trademark office and the Federal Circuit relating to a therapeutic antibody approved for the treatment of autoimmune disorders.
  • Drafted and prosecuted to issuance first patents directed to cloning and nuclear transfer on behalf of a major research university and its exclusive licensee.
  • Represented a major research university in an interference matter involving real-time polymerase chain reaction techniques. Obtained a non-interference in fact ruling favorable to the client.
  • Provide IP counseling and supporting opinions for numerous biotechnology and pharmaceutical clients, especially Hatch-Waxman litigation related matters.
  • Conducted numerous due diligence investigations, including one involving a major patent acquisition by a pharmaceutical company that resulted in the client acquiring a large patent estate (over 800 patents) and significantly streamlining the portfolio in order to minimize patent costs while maintaining key strategic patents.
  • Drafted and prosecuted to declaration of interference (4-party) a pioneering patent relating to a cervical cancer vaccine on behalf of a prominent university that was licensed by a prominent biotechnology company.
  • Prepared and filed numerous patent term extensions for biologics and pharmaceuticals.
  • Co-represented a company at the forefront of stem cell technology and nuclear transfer cloning in a 3-way interference involving pioneering nuclear transfer cloning technology.
  • Managed and prosecuted IP portfolio for company at the forefront of taste and olfactory receptor technology, which was one of very few biotechnology companies to successfully go public in 2004.
  • Manage the IP portfolio for a company involved in therapeutic antibodies, Pichia expression and novel platform technology for producing antibody secreting B cells and high affinity therapeutic antibodies.
  • Involved in numerous due diligences involving acquisition of IP portfolios of emerging and mid-sized biotechnology companies.

Reported Cases

  • Noelle v Lederman, 365 F3d 1343, Fed. Cir. 2004
  • Infigen v Advanced Cell Technology, Wisconsin West District Court 1999

Published Works

  • Legal Times, Volume XXVI, No. 44, “It Lives for 29 Years," a discussion of the patent term Cabilly Genentech Antibody Patent and its effects onn the industry.
  • A Historical Perspective of Nuclear Transfer Cloning, Teskin R, Cibelli JB, CABI Publishing, New York, 2002

Legal Experience

  • LeClairRyan, Alexandria, Virginia 2013 – Present
  • Hunton & Williams, McLean, Virginia, 2006 – 2013

Memberships and Affiliations

  • American Bar Association
  • District of Columbia Bar Association
  • Association of University Technology Managers
  • Intellectual Property Owners Association


  • Named Virginia Business magazine's "Legal Elite" in Intellectual Property Law, 2013
  • Bronze Medal, USPTO
  • Examiner on US Patent No. 5,000,000